Bloomberg has a good round up of several emerging pharmaceutical companies developing antibiotics. As the article notes, Big Pharma has largely moved away from antibiotic development for a number of commercial reasons. But, the unmet needs are still there, creating opportunities for product development.
This is good news, as the demand for novel antibiotics will only increase, especially as resistance remains a problem.